New MS drug study aims to confirm benefits for chinese patients
NCT ID NCT07353216
Summary
This study is observing how well the approved MS medication ofatumumab works and how safe it is for Chinese patients in real-world settings. It will follow 80 adults with relapsing MS to see if the drug reduces a blood marker linked to nerve damage. The goal is to gather more evidence on the drug's timing and effectiveness for this specific population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Third Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.